In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
Mark A. Kay, Charles N. Landen, Steven Rothenberg et al. · Proceedings of the National Academy of Sciences · 1994
Hemophilia B is a bleeding disorder caused by mutations in the factor IX gene. The disorder is X-linked recessive with a prevalence of about 1 in 30,000 Caucasian males. Factor IX is naturally synthesized in the liver and secreted into blood. Here we report the construction of recombinant adenoviral vectors containing the canine factor IX cDNA that are capable of transducing hepatocytes in mice at high efficiencies in vivo without partial hepatectomy. The recombinant viral vector was used to treat hemophilia B dogs by direct vector infusion into the portal vasculature of deficient animals. Plasma factor IX concentrations in the treated hemophilia B dogs increased from 0 to 300% of the level present in normal dogs, resulting in complete amelioration of the disease as demonstrated by normal blood coagulation and hemostatic measurements. Although plasma factor IX concentration started to decline after a few days, therapeutic levels of factor IX persisted for 1-2 months in the treated animals. The results validate the principle of in vivo hepatic gene delivery to reconstitute the genetic deficiency in a large animal model and suggest that gene therapy is achievable when long-acting vectors are developed.
Cited by 251 works. doi:10.1073/pnas.91.6.2353 Open-access PDF
Authors
- Mark A. Kay
- Charles N. Landen
- Steven Rothenberg
- Lorna A. Taylor
- Frances E. Leland
- Sandra Wiehle
- B Fang
- Dwight A. Bellinger
- Milton J. Finegold
- Arthur R. Thompson
References
- Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.
- Widespread long-term gene transfer to mouse skeletal muscles and heart.
- A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5
- Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice.
- Adenovirus–mediated in vivo gene transfer and expression in normal rat liver
- Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo.
- Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy
- Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes.
- In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
- Expression of human factor IX in mice after injection of genetically modified myoblasts.